Taro Pharmaceutical Industries Ltd.
TARO · NYSE
3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | $53,867 | $25,445 | $58,266 | -$400,740 |
| Dep. & Amort. | $31,094 | $32,127 | $25,915 | $23,680 |
| Deferred Tax | $19,148 | $16,802 | $23,200 | -$38,413 |
| Stock-Based Comp. | $0 | $0 | $0 | $0 |
| Change in WC | $28,100 | -$37,907 | -$279,040 | $460,659 |
| Other Non-Cash | $34,267 | -$4,717 | $12,961 | $584 |
| Operating Cash Flow | $132,388 | $31,750 | -$158,698 | $45,770 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$54,218 | -$17,847 | -$12,039 | -$17,144 |
| Net Acquisitions | $0 | -$1,976 | -$91,872 | $161 |
| Inv. Purchases | -$1,500 | -$107,709 | -$66,670 | -$1,132,501 |
| Inv. Sales/Matur. | $140,061 | $866,446 | $809,119 | $1,217,386 |
| Other Inv. Act. | $138,314 | -$864,470 | -$809,119 | -$161 |
| Investing Cash Flow | $84,343 | -$125,556 | -$170,581 | $67,741 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $0 | $0 | $0 | $0 |
| Stock Issued | $0 | $0 | $0 | $0 |
| Stock Repurch. | $0 | $0 | -$24,934 | -$24,196 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | $0 | $0 | -$24,934 | -$24,196 |
| Financing Cash Flow | $0 | $0 | -$24,934 | -$24,196 |
| Forex Effect | -$483 | -$2,833 | $170 | $2,508 |
| Net Chg. in Cash | $208,414 | -$96,639 | -$354,043 | $91,823 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $154,495 | $251,134 | $605,177 | $513,354 |
| End Cash | $362,909 | $154,495 | $251,134 | $605,177 |
| Free Cash Flow | $78,170 | $13,903 | -$170,737 | $28,626 |